Get the Stockscreener App
0.3053
3.53%
0.0104
After Hours:
.31
0.0047
+1.54%
Ovid Therapeutics Inc stock is traded at $0.3053, with a volume of 489.76K.
It is up +3.53% in the last 24 hours and up +6.60% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$0.2949
Open:
$0.292
24h Volume:
489.76K
Relative Volume:
1.30
Market Cap:
$20.91M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.4071
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+3.84%
1M Performance:
+6.60%
6M Performance:
-71.20%
1Y Performance:
-90.80%
1-Day Range:
$0.2904
$0.3062
1-Week Range:
$0.2807
$0.33
52-Week Range:
$0.2425
$3.4099
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.3053 | 20.91M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Ovid Therapeutics (OVID) Exceeds Q1 Revenue Expectations and Adv - GuruFocus
Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | - GuruFocus
Ovid Therapeutics Reports Business Updates and First Quarter 202 - GuruFocus
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc Reports Q1 2025 EPS of -$0.14, Meeting Est - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by Renaissance Technologies LLC - Defense World
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - ADVFN
Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World
Ovid Therapeutics Inc [OVID] stock for 2,956 USD was sold by ALEXANDER MARGARET A. - knoxdaily.com
The OVID Stock Puzzle: Unraveling Ovid Therapeutics Inc’s Fluctuating Performance - investchronicle.com
A closer look at Ovid Therapeutics Inc (OVID) is warranted - uspostnews.com
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
In Vivo’s 2025 Rising Leaders - insights.citeline.com
Ovid Therapeutics Advances Pipeline Amid Financial Progress - TipRanks
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Brain Medicine Updates: Ovid Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn - Investing.com Canada
HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics - Defense World
FY2026 Earnings Forecast for OVID Issued By HC Wainwright - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $4.00 at BTIG Research - Defense World
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Australia
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright - Investing.com
BTIG cuts Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com South Africa
BTIG cuts Ovid Therapeutics stock price target to $4 - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - GlobeNewswire
West syndrome Pipeline 2025: Mechanism of Action, Route - openPR
Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst - Defense World
What is Wedbush’s Estimate for OVID FY2029 Earnings? - Defense World
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):